The midyear deal results are in for biopharmaceutical sector, with both merger-and-acquisition and alliance activity up compared to 2023 but with valuations coming in somewhat lower. Scrip editors Joseph Haas, Mandy Jackson and Kevin Grogan overview M&A and alliance activity seen during the first six months of 2024 and project what to expect during the year’s second half.
Scrip M&A Podcast: Assessing The Biopharma Deals Environment At Midyear
With the first half of 2024 in the books, Scrip’s Joseph Haas, Mandy Jackson and Kevin Grogan discuss the dealmaking environment at the year’s midpoint and expectations for the second half.
More from Strategy
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
More from Business
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.